Amylyx Pharmaceuticals (AMLX)
(Delayed Data from NSDQ)
$8.19 USD
+0.01 (0.12%)
Updated Aug 6, 2025 04:00 PM ET
After-Market: $8.20 +0.01 (0.12%) 6:44 PM ET
3-Hold of 5 3
F Value B Growth D Momentum D VGM
Fundamental Charts
About PEG Ratio (TTM)
Currently, Amylyx Pharmaceuticals, Inc. has a PEG ratio of 0.13 compared to the Medical - Drugs industry's PEG ratio of 1.33.
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
AMLX 8.19 +0.01(0.12%)
Will AMLX be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for AMLX based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for AMLX
Wall Street Analysts See a 105.22% Upside in Amylyx Pharmaceuticals (AMLX): Can the Stock Really Move This High?
PSTV Stock Skyrockets on FDA's Orphan Drug Tag for Cancer Therapy
AMLX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Amylyx Pharmaceuticals (AMLX) Upgraded to Buy: What Does It Mean for the Stock?
Madrigal (MDGL) Reports Q2 Loss, Tops Revenue Estimates
Other News for AMLX
Here are the major earnings before the open Thursday
Amylyx Pharmaceuticals Q2 2025 Earnings Preview
Vanguard Group Inc's Strategic Acquisition in Amylyx Pharmaceuticals Inc
Amylyx Pharmaceuticals to Report Second Quarter 2025 Financial Results on August 7, 2025 | AMLX ...
BlackRock, Inc. Increases Stake in Amylyx Pharmaceuticals Inc.